Bloomgren G, Sperling B, Cushing K, & Wenten M. (2012). Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: Retrospective evaluation using a health insurance claims database and postmarketing surveillance data. Dove Medical Press.
Chicago Style (17th ed.) CitationBloomgren G, Sperling B, Cushing K, and Wenten M. Assessment of Malignancy Risk in Patients with Multiple Sclerosis Treated with Intramuscular Interferon Beta-1a: Retrospective Evaluation Using a Health Insurance Claims Database and Postmarketing Surveillance Data. Dove Medical Press, 2012.
MLA (9th ed.) CitationBloomgren G, et al. Assessment of Malignancy Risk in Patients with Multiple Sclerosis Treated with Intramuscular Interferon Beta-1a: Retrospective Evaluation Using a Health Insurance Claims Database and Postmarketing Surveillance Data. Dove Medical Press, 2012.